oncnursingnews1 天
JOAN SUCH LOCKHART, PHD, RN, AOCN, CNE, ANEF, FAAN
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews1 天
Top 5 Articles in 2024 for Oncology APPs and Nurses
Here are the top 5 articles from 2024 reported on Oncology Nursing News. Opinion: The Media May Have Oversold AOH1996, City ...
oncnursingnews3 天
Katie Goodman, RN, BSN, CCRP
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3 天
Pattie Jakel, MN, RN, AOCN
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews3 天
Angee Kilmer, BSN, RN-BC
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews3 天
Jeneth Aquino, DNP, APRN, FNP-BC
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews3 天
Marlon Garzo Saria, PhD, RN, AOCNS, FAAN
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews4 天
MANJULATA EVATT, DNP, RN, CMSRN
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews4 天
Toby Bressler, PhD, RN, OCN
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews4 天
Treatment Selection and Sequencing Strategies in HER2+ Metastatic Breast Cancer
Chemo Should be Tailored to Decrease Neuropathy in Black Patients ...
oncnursingnews5 天
Paige Soleimani, LMSW
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
oncnursingnews5 天
Bernardo L. Rapoport, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...